Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vamorolone - Santhera Pharmaceuticals

Drug Profile

Vamorolone - Santhera Pharmaceuticals

Alternative Names: AGAMREE; VB-15; VBP-15

Latest Information Update: 15 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ReveraGen BioPharma
  • Developer ReveraGen BioPharma; Santhera Pharmaceuticals
  • Class Anti-inflammatories; Antianaemics; Antiasthmatics; Antifibrotics; Antineoplastics; Antirheumatics; Corticosteroids; Glucocorticoids; Pregnatrienes; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Mineralocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Duchenne muscular dystrophy
  • Preclinical Unspecified
  • Discontinued Amyotrophic lateral sclerosis; Asthma; Brain cancer; Cystic fibrosis; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis; Sickle cell anaemia; Spinal muscular atrophy

Most Recent Events

  • 13 Mar 2024 Launched for Duchenne muscular dystrophy (In adolescents, In children, In the elderly, In adults) in USA (PO)
  • 14 Feb 2024 Efficacy data from a phase IIb VISION-DMD trial for Duchenne muscular dystrophy released by Santhera Pharmaceuticals
  • 15 Jan 2024 Launched for Duchenne muscular dystrophy (In adults, In children, In adolescents, In the elderly) in Germany (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top